Single Ascending Doses Study of Anti- Interleukin-7 Receptor α Monoclonal Antibody (GSK2618960) in Healthy Volunteers

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 0% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 9% of the time (238 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-09-01. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Accepts healthy volunteers: Yes (lowers risk) · Who can join
• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: ascendingsafety tolerabilitytolerability pharmacokineticssubjectspharmacodynamics
  Phrases that lowered it: healthyvaccinationvolunteerseffect ofimmunogenicity
• Design: parallel (raises risk) · Design
• Phase: 1 (lowers risk) · Design
• Sponsor's past trials: 2012 (raises risk) · Sponsor's track record
• Sponsor's past termination rate: 5.7% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 296 (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Has a data monitoring committee: No (lowers risk) · Design
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Disease area, cancer: No (lowers risk) · Disease area
• Maximum age: 65 (raises risk) · Who can join
• Number of arms: 4 (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design
• Blinding: double (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of GSK2330811 in Healthy Subjects NCT02386436 · started 2015 · scored riskier than 13% of active trials completed
• Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK2831781 After an Intravenous (IV) Dose in Healthy Japanese and Caucasian Subjects, and a Subcutaneous (SC) Dose in Healthy Caucasian Subjects NCT03965533 · started 2019 · scored riskier than 8% of active trials completed
• First Time in Human Study of Intravenous Interleukin-18 Antibody NCT01035645 · started 2010 · scored riskier than 4% of active trials completed
• A Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability, Immunogenicity, and Pharmacodynamics (PD) of GSK2800528 in Healthy Subjects. NCT01899755 · started 2013 · scored riskier than 4% of active trials completed
• Safety Study of GSK1995057 Given as Single and Repeat Intravenous Doses in Healthy Subjects. NCT01476046 · started 2011 · scored riskier than 6% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.